Piobot 15 Tablet contains Pioglitazone 15 mg, a thiazolidinedione-class oral antidiabetic drug that helps improve insulin sensitivity in the body. It effectively controls blood sugar levels in type 2 diabetes mellitus patients by enhancing glucose uptake in muscle and adipose tissue while reducing hepatic glucose production.
This medication is commonly prescribed as part of combination therapy with other oral antidiabetics like Metformin or Sulfonylureas to achieve optimal glycemic control. It supports long-term management of diabetes and helps reduce the risk of complications such as neuropathy, retinopathy, and cardiovascular disease.
Belonging to the antidiabetic and endocrinology segment, Piobot 15 Tablet is widely trusted by physicians for its sustained efficacy and tolerability. It offers a stable market opportunity for hospitals, clinics, and pharmacy distributors due to its consistent prescription demand.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Piobot 15 Tablet represents a high-demand, low-return-risk product ideal for expanding business portfolios in the diabetes care domain. Its clinical reliability and profitability make it a cornerstone product in any antidiabetic range.